These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 10333054)

  • 1. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations.
    Hammes HP; Brownlee M; Lin J; Schleicher E; Bretzel RG
    Diabetologia; 1999 May; 42(5):603-7. PubMed ID: 10333054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes.
    Miura J; Yamagishi Si; Uchigata Y; Takeuchi M; Yamamoto H; Makita Z; Iwamoto Y
    J Diabetes Complications; 2003; 17(1):16-21. PubMed ID: 12505751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study.
    Schram MT; Schalkwijk CG; Bootsma AH; Fuller JH; Chaturvedi N; Stehouwer CD;
    Hypertension; 2005 Jul; 46(1):232-7. PubMed ID: 15851628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitreous advanced glycation endproducts and α-dicarbonyls in retinal detachment patients with type 2 diabetes mellitus and non-diabetic controls.
    Fokkens BT; Mulder DJ; Schalkwijk CG; Scheijen JL; Smit AJ; Los LI
    PLoS One; 2017; 12(3):e0173379. PubMed ID: 28264049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes.
    Berg TJ; Clausen JT; Torjesen PA; Dahl-Jørgensen K; Bangstad HJ; Hanssen KF
    Diabetes Care; 1998 Nov; 21(11):1997-2002. PubMed ID: 9802757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
    Ghanem AA; Elewa A; Arafa LF
    Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
    Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum advanced glycation endproducts are associated with left ventricular dysfunction in normal glucose metabolism but not in type 2 diabetes: The Hoorn Study.
    Linssen PB; Henry RM; Schalkwijk CG; Dekker JM; Nijpels G; Brunner-La Rocca HP; Stehouwer CD
    Diab Vasc Dis Res; 2016 Jul; 13(4):278-85. PubMed ID: 27190078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes.
    Ahmed N; Babaei-Jadidi R; Howell SK; Thornalley PJ; Beisswenger PJ
    Diabetes Care; 2005 Oct; 28(10):2465-71. PubMed ID: 16186281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes.
    Koska J; Saremi A; Howell S; Bahn G; De Courten B; Ginsberg H; Beisswenger PJ; Reaven PD;
    Diabetes Care; 2018 Mar; 41(3):570-576. PubMed ID: 29208654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study.
    Saremi A; Howell S; Schwenke DC; Bahn G; Beisswenger PJ; Reaven PD;
    Diabetes Care; 2017 Apr; 40(4):591-598. PubMed ID: 28148544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies against advanced glycation end product Nepsilon-(carboxymethyl)lysine in healthy controls and diabetic patients.
    Vay D; Vidali M; Allochis G; Cusaro C; Rolla R; Mottaran E; Bellomo G; Albano E
    Diabetologia; 2000 Nov; 43(11):1385-8. PubMed ID: 11126407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA.
    Galler A; Müller G; Schinzel R; Kratzsch J; Kiess W; Münch G
    Diabetes Care; 2003 Sep; 26(9):2609-15. PubMed ID: 12941727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy.
    Endo M; Yanagisawa K; Tsuchida K; Okamoto T; Matsushita T; Higuchi M; Matsuda A; Takeuchi M; Makita Z; Koike T
    Horm Metab Res; 2001 May; 33(5):317-22. PubMed ID: 11440280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased levels of N(ε)- Carboxy methyl lysine (N(ε)-CML) are associated with topographic alterations in retinal pigment epithelium: A preliminary study.
    Mishra N; Saxena S; Ruia S; Prasad S; Singh V; Khanna V; Staffa R; Gaspar L; Kruzliak P
    J Diabetes Complications; 2016 Jul; 30(5):868-72. PubMed ID: 27039312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema.
    Boehm BO; Schilling S; Rosinger S; Lang GE; Lang GK; Kientsch-Engel R; Stahl P
    Diabetologia; 2004 Aug; 47(8):1376-9. PubMed ID: 15258735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas.
    Murata T; Nagai R; Ishibashi T; Inomuta H; Ikeda K; Horiuchi S
    Diabetologia; 1997 Jul; 40(7):764-9. PubMed ID: 9243096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentosidine - a new biochemical marker in diabetic retinopathy.
    Salman AG; Mansour DE; Swelem AH; Al-Zawahary WM; Radwan AA
    Ophthalmic Res; 2009; 42(2):96-8. PubMed ID: 19546600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine- and Nepsilon-(1-carboxyethyl)lysine-modified albumin.
    Ahmed N; Argirov OK; Minhas HS; Cordeiro CA; Thornalley PJ
    Biochem J; 2002 May; 364(Pt 1):1-14. PubMed ID: 11988070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.